FINWIRES · TerminalLIVE
FINWIRES

Better Home & Finance Shares Fall as Ex-CEO Pushes to Remove Five Directors

By

Better Home & Finance (BETR) shares fell over 1% on Tuesday after former chief executive Vishal Garg criticized the company's actions related to his effort to remove five directors from its board.

Garg urged shareholders to submit their consent to support proposals to remove directors Daniel Lewis, Harit Talwar, Arnaud Massenet, Bhaskar Menon and Prabhu Narasimhan, according to a statement.

Garg said, despite the company's efforts, the campaign has already received support from shareholders representing more than 46% of Better's voting power.

He added that he seeks to nominate new independent candidates, including Bing Gordon, David Heidecorn and Steve Sarracino.

Better Home & Finance didn't immediately reply to' request for comment.

Price: $12.37, Change: $-0.05, Percent Change: -0.40%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA